PMC:7455778 / 18447-19735 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T33","span":{"begin":758,"end":764},"obj":"Body_part"},{"id":"T34","span":{"begin":968,"end":991},"obj":"Body_part"}],"attributes":[{"id":"A33","pred":"fma_id","subj":"T33","obj":"http://purl.org/sig/ont/fma/fma54437"},{"id":"A34","pred":"fma_id","subj":"T34","obj":"http://purl.org/sig/ont/fma/fma45661"}],"text":"The differential diagnosis of SARS-CoV-2 conjunctivitis includes other viral conjunctivitis such as adenoviral conjunctivitis, based on our findings (Table 5). 54.29% of conjunctivitis were completely unilateral, unlike adenoviral conjunctivitis where there is a greater tendency to bilateralization [11]. However, bilateral conjunctivitis in COVID-19 has also been described [3].\nTable 5 Differential diagnosis between conjunctivitis in COVID-19 patients and adenoviral conjunctivitis\nConjunctivitis in COVID-19 Adenoviral conjunctivitis\nOnset Abrupt Abrupt\nUnilateral/bilateral Unilateral ++\nBilateral + Unilateral or bilateral (often sequentially bilateral)\nConjunctival injection Mild or very mild Varies in severity\nFollicular reaction + +\nChemosis ± ±\nEyelid swelling and erythema – ±\nConjunctival petechiae /subconjunctival hemorrhage – ±\nDischarge + ++\nEpithelial punctate keratitis – ±\nCorneal infiltrates – ±\nMembrane/pseudomembrane formation – ±\nConcurrent upper respiratory tract infection ± ±\nSymptoms Very mild-mild Mild-severe\nNatural history Self-limited within 2–4 days Self-limited within 5–14 days (could get worse during the first days)\nPotential sequelae Not Known Severe cases: conjunctival scarring, symblepharon, subepithelial corneal infiltrates, decreased vision"}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T12","span":{"begin":758,"end":764},"obj":"Body_part"},{"id":"T13","span":{"begin":968,"end":991},"obj":"Body_part"},{"id":"T14","span":{"begin":974,"end":991},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0001711"},{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0001557"},{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"}],"text":"The differential diagnosis of SARS-CoV-2 conjunctivitis includes other viral conjunctivitis such as adenoviral conjunctivitis, based on our findings (Table 5). 54.29% of conjunctivitis were completely unilateral, unlike adenoviral conjunctivitis where there is a greater tendency to bilateralization [11]. However, bilateral conjunctivitis in COVID-19 has also been described [3].\nTable 5 Differential diagnosis between conjunctivitis in COVID-19 patients and adenoviral conjunctivitis\nConjunctivitis in COVID-19 Adenoviral conjunctivitis\nOnset Abrupt Abrupt\nUnilateral/bilateral Unilateral ++\nBilateral + Unilateral or bilateral (often sequentially bilateral)\nConjunctival injection Mild or very mild Varies in severity\nFollicular reaction + +\nChemosis ± ±\nEyelid swelling and erythema – ±\nConjunctival petechiae /subconjunctival hemorrhage – ±\nDischarge + ++\nEpithelial punctate keratitis – ±\nCorneal infiltrates – ±\nMembrane/pseudomembrane formation – ±\nConcurrent upper respiratory tract infection ± ±\nSymptoms Very mild-mild Mild-severe\nNatural history Self-limited within 2–4 days Self-limited within 5–14 days (could get worse during the first days)\nPotential sequelae Not Known Severe cases: conjunctival scarring, symblepharon, subepithelial corneal infiltrates, decreased vision"}

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T146","span":{"begin":261,"end":262},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T147","span":{"begin":301,"end":303},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T148","span":{"begin":352,"end":355},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T149","span":{"begin":861,"end":871},"obj":"http://purl.obolibrary.org/obo/CL_0000066"},{"id":"T150","span":{"begin":919,"end":927},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T151","span":{"begin":1107,"end":1111},"obj":"http://purl.obolibrary.org/obo/CLO_0001406"}],"text":"The differential diagnosis of SARS-CoV-2 conjunctivitis includes other viral conjunctivitis such as adenoviral conjunctivitis, based on our findings (Table 5). 54.29% of conjunctivitis were completely unilateral, unlike adenoviral conjunctivitis where there is a greater tendency to bilateralization [11]. However, bilateral conjunctivitis in COVID-19 has also been described [3].\nTable 5 Differential diagnosis between conjunctivitis in COVID-19 patients and adenoviral conjunctivitis\nConjunctivitis in COVID-19 Adenoviral conjunctivitis\nOnset Abrupt Abrupt\nUnilateral/bilateral Unilateral ++\nBilateral + Unilateral or bilateral (often sequentially bilateral)\nConjunctival injection Mild or very mild Varies in severity\nFollicular reaction + +\nChemosis ± ±\nEyelid swelling and erythema – ±\nConjunctival petechiae /subconjunctival hemorrhage – ±\nDischarge + ++\nEpithelial punctate keratitis – ±\nCorneal infiltrates – ±\nMembrane/pseudomembrane formation – ±\nConcurrent upper respiratory tract infection ± ±\nSymptoms Very mild-mild Mild-severe\nNatural history Self-limited within 2–4 days Self-limited within 5–14 days (could get worse during the first days)\nPotential sequelae Not Known Severe cases: conjunctival scarring, symblepharon, subepithelial corneal infiltrates, decreased vision"}

LitCovid-PD-HP

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T6","span":{"begin":943,"end":952},"obj":"http://purl.obolibrary.org/obo/GO_0009058"},{"id":"T7","span":{"begin":1282,"end":1288},"obj":"http://purl.obolibrary.org/obo/GO_0007601"}],"text":"The differential diagnosis of SARS-CoV-2 conjunctivitis includes other viral conjunctivitis such as adenoviral conjunctivitis, based on our findings (Table 5). 54.29% of conjunctivitis were completely unilateral, unlike adenoviral conjunctivitis where there is a greater tendency to bilateralization [11]. However, bilateral conjunctivitis in COVID-19 has also been described [3].\nTable 5 Differential diagnosis between conjunctivitis in COVID-19 patients and adenoviral conjunctivitis\nConjunctivitis in COVID-19 Adenoviral conjunctivitis\nOnset Abrupt Abrupt\nUnilateral/bilateral Unilateral ++\nBilateral + Unilateral or bilateral (often sequentially bilateral)\nConjunctival injection Mild or very mild Varies in severity\nFollicular reaction + +\nChemosis ± ±\nEyelid swelling and erythema – ±\nConjunctival petechiae /subconjunctival hemorrhage – ±\nDischarge + ++\nEpithelial punctate keratitis – ±\nCorneal infiltrates – ±\nMembrane/pseudomembrane formation – ±\nConcurrent upper respiratory tract infection ± ±\nSymptoms Very mild-mild Mild-severe\nNatural history Self-limited within 2–4 days Self-limited within 5–14 days (could get worse during the first days)\nPotential sequelae Not Known Severe cases: conjunctival scarring, symblepharon, subepithelial corneal infiltrates, decreased vision"}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T178","span":{"begin":0,"end":159},"obj":"Sentence"},{"id":"T179","span":{"begin":160,"end":305},"obj":"Sentence"},{"id":"T180","span":{"begin":306,"end":380},"obj":"Sentence"},{"id":"T181","span":{"begin":381,"end":485},"obj":"Sentence"},{"id":"T182","span":{"begin":486,"end":538},"obj":"Sentence"},{"id":"T183","span":{"begin":539,"end":558},"obj":"Sentence"},{"id":"T184","span":{"begin":559,"end":593},"obj":"Sentence"},{"id":"T185","span":{"begin":594,"end":660},"obj":"Sentence"},{"id":"T186","span":{"begin":661,"end":720},"obj":"Sentence"},{"id":"T187","span":{"begin":721,"end":744},"obj":"Sentence"},{"id":"T188","span":{"begin":745,"end":757},"obj":"Sentence"},{"id":"T189","span":{"begin":758,"end":790},"obj":"Sentence"},{"id":"T190","span":{"begin":791,"end":845},"obj":"Sentence"},{"id":"T191","span":{"begin":846,"end":860},"obj":"Sentence"},{"id":"T192","span":{"begin":861,"end":894},"obj":"Sentence"},{"id":"T193","span":{"begin":895,"end":918},"obj":"Sentence"},{"id":"T194","span":{"begin":919,"end":956},"obj":"Sentence"},{"id":"T195","span":{"begin":957,"end":1005},"obj":"Sentence"},{"id":"T196","span":{"begin":1006,"end":1041},"obj":"Sentence"},{"id":"T197","span":{"begin":1042,"end":1156},"obj":"Sentence"},{"id":"T198","span":{"begin":1157,"end":1288},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The differential diagnosis of SARS-CoV-2 conjunctivitis includes other viral conjunctivitis such as adenoviral conjunctivitis, based on our findings (Table 5). 54.29% of conjunctivitis were completely unilateral, unlike adenoviral conjunctivitis where there is a greater tendency to bilateralization [11]. However, bilateral conjunctivitis in COVID-19 has also been described [3].\nTable 5 Differential diagnosis between conjunctivitis in COVID-19 patients and adenoviral conjunctivitis\nConjunctivitis in COVID-19 Adenoviral conjunctivitis\nOnset Abrupt Abrupt\nUnilateral/bilateral Unilateral ++\nBilateral + Unilateral or bilateral (often sequentially bilateral)\nConjunctival injection Mild or very mild Varies in severity\nFollicular reaction + +\nChemosis ± ±\nEyelid swelling and erythema – ±\nConjunctival petechiae /subconjunctival hemorrhage – ±\nDischarge + ++\nEpithelial punctate keratitis – ±\nCorneal infiltrates – ±\nMembrane/pseudomembrane formation – ±\nConcurrent upper respiratory tract infection ± ±\nSymptoms Very mild-mild Mild-severe\nNatural history Self-limited within 2–4 days Self-limited within 5–14 days (could get worse during the first days)\nPotential sequelae Not Known Severe cases: conjunctival scarring, symblepharon, subepithelial corneal infiltrates, decreased vision"}

2_test

{"project":"2_test","denotations":[{"id":"32860573-32210533-45244302","span":{"begin":301,"end":303},"obj":"32210533"},{"id":"T79487","span":{"begin":301,"end":303},"obj":"32210533"}],"text":"The differential diagnosis of SARS-CoV-2 conjunctivitis includes other viral conjunctivitis such as adenoviral conjunctivitis, based on our findings (Table 5). 54.29% of conjunctivitis were completely unilateral, unlike adenoviral conjunctivitis where there is a greater tendency to bilateralization [11]. However, bilateral conjunctivitis in COVID-19 has also been described [3].\nTable 5 Differential diagnosis between conjunctivitis in COVID-19 patients and adenoviral conjunctivitis\nConjunctivitis in COVID-19 Adenoviral conjunctivitis\nOnset Abrupt Abrupt\nUnilateral/bilateral Unilateral ++\nBilateral + Unilateral or bilateral (often sequentially bilateral)\nConjunctival injection Mild or very mild Varies in severity\nFollicular reaction + +\nChemosis ± ±\nEyelid swelling and erythema – ±\nConjunctival petechiae /subconjunctival hemorrhage – ±\nDischarge + ++\nEpithelial punctate keratitis – ±\nCorneal infiltrates – ±\nMembrane/pseudomembrane formation – ±\nConcurrent upper respiratory tract infection ± ±\nSymptoms Very mild-mild Mild-severe\nNatural history Self-limited within 2–4 days Self-limited within 5–14 days (could get worse during the first days)\nPotential sequelae Not Known Severe cases: conjunctival scarring, symblepharon, subepithelial corneal infiltrates, decreased vision"}

LitCovid-PMC-OGER-BB

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T74","span":{"begin":170,"end":181},"obj":"SP_7"},{"id":"T76","span":{"begin":958,"end":984},"obj":"UBERON:0000970"},{"id":"T93","span":{"begin":897,"end":902},"obj":"NCBITaxon:10239"},{"id":"T132","span":{"begin":19,"end":29},"obj":"NCBITaxon:10508"},{"id":"T133","span":{"begin":139,"end":149},"obj":"NCBITaxon:10508"},{"id":"T134","span":{"begin":262,"end":270},"obj":"SP_7"},{"id":"T135","span":{"begin":355,"end":363},"obj":"SP_7"},{"id":"T136","span":{"begin":377,"end":387},"obj":"NCBITaxon:10508"},{"id":"T137","span":{"begin":420,"end":438},"obj":"SP_7"},{"id":"T138","span":{"begin":656,"end":662},"obj":"UBERON:0001711"},{"id":"T139","span":{"begin":708,"end":723},"obj":"UBERON:0003893"},{"id":"T140","span":{"begin":748,"end":757},"obj":"UBERON:0000483"},{"id":"T141","span":{"begin":847,"end":870},"obj":"UBERON:0001557"},{"id":"T142","span":{"begin":1069,"end":1081},"obj":"UBERON:0001811"},{"id":"T143","span":{"begin":1106,"end":1126},"obj":"UBERON:0001772"},{"id":"T144","span":{"begin":1150,"end":1156},"obj":"GO:0007601"},{"id":"T145","span":{"begin":1214,"end":1222},"obj":"SP_7"},{"id":"T146","span":{"begin":1236,"end":1247},"obj":"NCBITaxon:10508"}],"text":"The differential diagnosis of SARS-CoV-2 conjunctivitis includes other viral conjunctivitis such as adenoviral conjunctivitis, based on our findings (Table 5). 54.29% of conjunctivitis were completely unilateral, unlike adenoviral conjunctivitis where there is a greater tendency to bilateralization [11]. However, bilateral conjunctivitis in COVID-19 has also been described [3].\nTable 5 Differential diagnosis between conjunctivitis in COVID-19 patients and adenoviral conjunctivitis\nConjunctivitis in COVID-19 Adenoviral conjunctivitis\nOnset Abrupt Abrupt\nUnilateral/bilateral Unilateral ++\nBilateral + Unilateral or bilateral (often sequentially bilateral)\nConjunctival injection Mild or very mild Varies in severity\nFollicular reaction + +\nChemosis ± ±\nEyelid swelling and erythema – ±\nConjunctival petechiae /subconjunctival hemorrhage – ±\nDischarge + ++\nEpithelial punctate keratitis – ±\nCorneal infiltrates – ±\nMembrane/pseudomembrane formation – ±\nConcurrent upper respiratory tract infection ± ±\nSymptoms Very mild-mild Mild-severe\nNatural history Self-limited within 2–4 days Self-limited within 5–14 days (could get worse during the first days)\nPotential sequelae Not Known Severe cases: conjunctival scarring, symblepharon, subepithelial corneal infiltrates, decreased vision"}

LitCovid-PubTator

PMC:7455778 / 18447-19735 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7455778 / 18447-19735 JSON TXT